Literature DB >> 24094713

Current and future trends in the anatomical and functional imaging of head and neck paragangliomas.

David Taïeb1, Arthur Varoquaux, Clara C Chen, Karel Pacak.   

Abstract

Head and neck paragangliomas (HNPGLs) account for approximately 3% of all paragangliomas (PGLs). Most often, HNPGLs are benign, nonsecreting, and slowly progressing. The initial physical examination and biochemical diagnosis usually adds very little to the proper diagnosis of these tumors, and, therefore, radiologists and nuclear medicine physicians play a pivotal role in providing the initial diagnosis, the locoregional staging, and the plan for detecting potential multicentric or metastatic lesions. Based on several current studies, the most accurate use of HNPGL-specific initial and subsequent imaging modalities must be guided by the knowledge of genetics and the specifically measured biochemical profile of these tumors for the proper management of these patients. Thus, this short review article presents the application of the most up-to-date anatomical and functional imaging approaches to HNPGLs tightly linked to the clinical management of these patients. Based on the most recent studies, 18F-FDOPA PET/CT has been shown to be a useful addition to anatomical imaging in the preoperative localization and molecular assessment of HNPGLs. It is estimated that the frequency of metabolically active PGLs on 18F-FDOPA PET/CT in this region is higher than 90%. For patients with hereditary PGL syndromes, (18)F-FDG-PET/CT should be reserved. Imaging of somatostatin receptors using Octreoscan or 68Ga-labeled somatostatin analogues plays an important role for selecting patients for targeted radiation therapy. This review also concludes that it is expected that in the near future, these patients will indeed benefit from new diagnostic approaches based on the identification of new targets by molecular profiling studies that will result in the development of novel PGL-specific radiopharmaceuticals. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2013        PMID: 24094713      PMCID: PMC3792493          DOI: 10.1053/j.semnuclmed.2013.06.005

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  68 in total

1.  Comparison of [¹¹¹In]pentetreotide-SPECT and [¹⁸F]FDOPA-PET in the localization of extra-adrenal paragangliomas: the case for a patient-tailored use of nuclear imaging modalities.

Authors:  N Charrier; A Deveze; N Fakhry; F Sebag; I Morange; B Gaborit; A Barlier; E Carmona; C De Micco; S Garcia; J Mancini; F F Palazzo; J P Lavieille; M Zanaret; J F Henry; O Mundler; D Taïeb
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

Review 2.  Successful treatment of glomus jugulare tumours with gamma knife radiosurgery: clinical and physical aspects of management and review of the literature.

Authors:  Arturo Navarro Martín; Ann Maitz; Inga S Grills; Dennis Bojrab; Jack Kartush; Peter Y Chen; Joav Hahn; Daniel Pieper
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

Review 3.  Treatment of glomus jugulare tumors with gamma knife radiosurgery.

Authors:  Philip G Chen; James H Nguyen; Spencer C Payne; Jason P Sheehan; George T Hashisaki
Journal:  Laryngoscope       Date:  2010-09       Impact factor: 3.325

4.  Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites.

Authors:  Hartmut P H Neumann; Maren Sullivan; Aurelia Winter; Angelica Malinoc; Michael M Hoffmann; Carsten C Boedeker; Hartmut Bertz; Martin K Walz; Lars C Moeller; Kurt W Schmid; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2011-05-25       Impact factor: 5.958

5.  SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma.

Authors:  Henricus P M Kunst; Martijn H Rutten; Jan-Pieter de Mönnink; Lies H Hoefsloot; Henri J L M Timmers; Henri A M Marres; Jeroen C Jansen; Hannie Kremer; Jean-Pierre Bayley; Cor W R J Cremers
Journal:  Clin Cancer Res       Date:  2011-01-11       Impact factor: 12.531

6.  68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours.

Authors:  Meeran Naji; Chunlei Zhao; Sarah J Welsh; Richard Meades; Zarni Win; Annalisa Ferrarese; Tricia Tan; Domenico Rubello; Adil Al-Nahhas
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

7.  Paragangliomas of head and neck: a treatment option with CyberKnife radiosurgery.

Authors:  Livia C Bianchi; Marcello Marchetti; Lorenzo Brait; Achille Bergantin; Ida Milanesi; Giovanni Broggi; Laura Fariselli
Journal:  Neurol Sci       Date:  2009-09-23       Impact factor: 3.307

8.  SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma.

Authors:  Huai-Xiang Hao; Oleh Khalimonchuk; Margit Schraders; Noah Dephoure; Jean-Pierre Bayley; Henricus Kunst; Peter Devilee; Cor W R J Cremers; Joshua D Schiffman; Brandon G Bentz; Steven P Gygi; Dennis R Winge; Hannie Kremer; Jared Rutter
Journal:  Science       Date:  2009-07-23       Impact factor: 47.728

9.  Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.

Authors:  Henri J L M Timmers; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Bastiaan Havekes; Graeme Eisenhofer; Lucia Martiniova; Karen T Adams; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2009-10-28       Impact factor: 5.958

10.  Parasympathetic paragangliomas are part of the Von Hippel-Lindau syndrome.

Authors:  José Gaal; Francien H van Nederveen; Zoran Erlic; Esther Korpershoek; Rogier Oldenburg; Carsten C Boedeker; Udo Kontny; Hartmut P Neumann; Winand N M Dinjens; Ronald R de Krijger
Journal:  J Clin Endocrinol Metab       Date:  2009-10-06       Impact factor: 5.958

View more
  9 in total

Review 1.  Somatostatin receptor expression in non-classical locations - clinical relevance?

Authors:  Eldrin Bhanat; Christian A Koch; Rinkuben Parmar; Vishnu Garla; Vani Vijayakumar
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 2.  [Diagnosis and treatment of glomus tumors of the skull base and neck].

Authors:  Wolfgang Reith; Michael Kettner
Journal:  Radiologe       Date:  2019-12       Impact factor: 0.635

Review 3.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

4.  [Percutaneous embolization and ultrasound scissors for removal of a carotid body tumor].

Authors:  I I Venara-Vulpe; B Morisod; G B Morand; J-B Zerlauth; C Simon
Journal:  HNO       Date:  2016-12       Impact factor: 1.284

5.  Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics.

Authors:  Arthur Varoquaux; Yann le Fur; Alessio Imperiale; Antony Reyre; Marion Montava; Nicolas Fakhry; Izzie-Jacques Namer; Guy Moulin; Karel Pacak; Maxime Guye; David Taïeb
Journal:  Endocr Relat Cancer       Date:  2015-06-26       Impact factor: 5.678

6.  18F-FDG PET/CT as a predictor of hereditary head and neck paragangliomas.

Authors:  Karel Pacak; David Taïeb; Elise M Blanchet; Sophie Gabriel; Victoria Martucci; Nicolas Fakhry; Clara C Chen; Arnaud Deveze; Corina Millo; Anne Barlier; Morgane Pertuit; Anderson Loundou
Journal:  Eur J Clin Invest       Date:  2014       Impact factor: 4.686

Review 7.  Diagnostic Investigation of Lesions Associated with Succinate Dehydrogenase Defects.

Authors:  David Taïeb; Henri Timmers; Karel Pacak
Journal:  Horm Metab Res       Date:  2018-04-04       Impact factor: 2.936

8.  Does Octreoscan add value in the differential diagnosis of parapharyngeal space lesions?

Authors:  Raquel Baptista Dias; Alexandra Borges
Journal:  Radiol Bras       Date:  2021 Nov-Dec

Review 9.  Functional Imaging of Paragangliomas with an Emphasis on Von Hippel-Lindau-Associated Disease: A Mini Review.

Authors:  Ioannis Ilias; Georgios Meristoudis
Journal:  J Kidney Cancer VHL       Date:  2017-09-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.